Journal of Oncology Research and Therapy (ISSN: 2574-710X)

research article

Glyco-polypeptides in Treating of Various Types of Late-Stage Refractory Solid Carcinoma in Humans-A Double-Blind Study-Case Report of 126 Patients: Complete Study Report of Phase II Clinical Trial

Benedict S Liao1*, Elizabeth Harvowitz2, Michael Fishbein3, Austin Liao4, Alex Liao4, Burton Liao4, Judy F-C Li4

*Corresponding Author: Benedict S. Liao, Director of Molecular Biology & Immunology, Oeyama-Moto Cancer Research Foundation, 3106 E Garvey Ave, South West Covina, CA, 91791, USA

Received Date: September 19, 2021

Accepted Date: October 18, 2021

Published Date: October 22, 2021

Abstract

Glyco-polypeptides (Comosain) induced leucocyte binding ability to tumor surface antigens, such as interleukin 2, 6, 8, and TNFs, is known as an immuno-target therapy. Using the different concentration of Bromelain proteinases in 6 types of cancer cell, it resulted in hydrolysis, fibrinolysis, necrosis, and anti-metastatic effects in tumor cells. Anti-cancer effects were achieved in carcinoma of lung, breast, colon, ovary, cervix, and uterus. Investigation of anti-metastatic effects in Bromelain was carried out in a double-blind study: low dose cohort was on 10 mg/kg/day and a high dose cohort which was on 50 mg/kg/day for over six months. A total of 151 patients with 3rd and 4th stage of refractory solid tumors were enrolled, 25 patients were post-surgery within 6 weeks which were excluded from entering this research who at least previously failed on two regimens of chemotherapy and/or failed on radiation therapy. The actual study patients were only 126 patients. The rates of Complete Response (CR) and Partial Responses (PR) in the high-dose cohort are astonishing with 52% and 27% respectively. The Progress Disease (PD) was 10%, and the Stable Disease (SD) was 11%. The implications and results of the findings are discussed in view of the reported anti-metastatic activity of orally administrated Bromelain.

Keywords: Glyco-polypeptides; Carcinoma; Clinical trial


Page Views: 11165743